These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1630720)

  • 1. Acetyl-carnitine and Alzheimer's disease.
    Bowman BA
    Nutr Rev; 1992 May; 50(5):142-4. PubMed ID: 1630720
    [No Abstract]   [Full Text] [Related]  

  • 2. Action of acetyl-L-carnitine in neurodegeneration and Alzheimer's disease.
    Calvani M; Carta A; Caruso G; Benedetti N; Iannuccelli M
    Ann N Y Acad Sci; 1992 Nov; 663():483-6. PubMed ID: 1482095
    [No Abstract]   [Full Text] [Related]  

  • 3. [The use of 1-acetylcarnitine in (presenile and senile) Alzheimer's disease. Preliminary results].
    Acierno G
    Clin Ter; 1983 Apr; 105(2):135-45. PubMed ID: 6345054
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease.
    Pettegrew JW; Klunk WE; Panchalingam K; Kanfer JN; McClure RJ
    Neurobiol Aging; 1995; 16(1):1-4. PubMed ID: 7723928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetyl-L-carnitine: a drug able to slow the progress of Alzheimer's disease?
    Carta A; Calvani M
    Ann N Y Acad Sci; 1991; 640():228-32. PubMed ID: 1776743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind, placebo controlled study of acetyl-l-carnitine in patients with Alzheimer's dementia.
    Rai G; Wright G; Scott L; Beston B; Rest J; Exton-Smith AN
    Curr Med Res Opin; 1990; 11(10):638-47. PubMed ID: 2178869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term acetyl-L-carnitine treatment in Alzheimer's disease.
    Spagnoli A; Lucca U; Menasce G; Bandera L; Cizza G; Forloni G; Tettamanti M; Frattura L; Tiraboschi P; Comelli M
    Neurology; 1991 Nov; 41(11):1726-32. PubMed ID: 1944900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicentre study of l-alpha-glyceryl-phosphorylcholine vs ST200 among patients with probable senile dementia of Alzheimer's type.
    Parnetti L; Abate G; Bartorelli L; Cucinotta D; Cuzzupoli M; Maggioni M; Villardita C; Senin U
    Drugs Aging; 1993; 3(2):159-64. PubMed ID: 8477148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease.
    Sano M; Bell K; Cote L; Dooneief G; Lawton A; Legler L; Marder K; Naini A; Stern Y; Mayeux R
    Arch Neurol; 1992 Nov; 49(11):1137-41. PubMed ID: 1444880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Acetyl-L-carnitine (carnicetine) in the treatment of early stages of Alzheimer's disease and vascular dementia].
    Gavrilova SI; Kalyn IaB; Kolykhalov IV; Roshchina IF; Selezneva ND
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(9):16-22. PubMed ID: 22027664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetyl-L-carnitine and Alzheimer's disease: pharmacological considerations beyond the cholinergic sphere.
    Carta A; Calvani M; Bravi D; Bhuachalla SN
    Ann N Y Acad Sci; 1993 Sep; 695():324-6. PubMed ID: 8239306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 1-year controlled trial of acetyl-L-carnitine in early-onset AD.
    Barrett AM
    Neurology; 2001 Feb; 56(3):425. PubMed ID: 11171924
    [No Abstract]   [Full Text] [Related]  

  • 13. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression.
    Pettegrew JW; Levine J; McClure RJ
    Mol Psychiatry; 2000 Nov; 5(6):616-32. PubMed ID: 11126392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An example of a clinical trial in patients with Alzheimer's disease: some methodological issues.
    Lucca U; Menasce G; Comelli M; Cizza G; Bressi S; Frattura L; Tiraboschi P; Spagnoli A
    Prog Clin Biol Res; 1989; 317():1301-10. PubMed ID: 2690098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetyl-L-carnitine.
    Altern Med Rev; 1999 Dec; 4(6):438-41. PubMed ID: 10608918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type.
    Parnetti L; Gaiti A; Mecocci P; Cadini D; Senin U
    Eur J Clin Pharmacol; 1992; 42(1):89-93. PubMed ID: 1541322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors.
    Bianchetti A; Rozzini R; Trabucchi M
    Curr Med Res Opin; 2003; 19(4):350-3. PubMed ID: 12841930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of acetyl-L-carnitine administration on persons with Down syndrome.
    Pueschel SM
    Res Dev Disabil; 2006; 27(6):599-604. PubMed ID: 16621446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetyl-L-carnitine in the treatment of mildly demented elderly patients.
    Passeri M; Cucinotta D; Bonati PA; Iannuccelli M; Parnetti L; Senin U
    Int J Clin Pharmacol Res; 1990; 10(1-2):75-9. PubMed ID: 2201659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of acetyl-L-carnitine infusion on haemodynamic parameters and survival of circulatory-shock patients.
    Gasparetto A; Corbucci GG; De Blasi RA; Antonelli M; Bagiella E; D'Iddio S; Trevisani C
    Int J Clin Pharmacol Res; 1991; 11(2):83-92. PubMed ID: 1879992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.